SHPH Shuttle Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1757499 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY15.5%
TTM EPS YoY158.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-90.1%
ROA-72.5%
ROIC (approx.)-99.2%
Asset turnover—
Leverage & solvency
Liabilities / assets15.9%
Debt / equity0.00x
Current ratio0.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-26.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $4.05M | $3.62M | $3.52M | $1.05M | $1.02M |
| SG&A expense | $5.67M | $1.39M | $1.05M | $473,714 | $36,500 |
| Operating income | -$11.92M | -$7.70M | -$5.89M | -$2.34M | -$1.74M |
| Interest expense | — | — | $2.12M | $917,879 | $3,841 |
| Pretax income | $11.43M | $9.14M | -$6.59M | -$5.00M | -$1.15M |
| Net income | -$11.72M | -$9.14M | -$6.59M | -$5.00M | -$1.15M |
| EBITDA | -$11.63M | -$7.69M | -$5.89M | -$2.34M | -$1.74M |
| EPS (basic) | -7.16 | -79.65 | -3.53 | -5.04 | -0.12 |
| EPS (diluted) | -7.16 | -82.60 | -3.53 | -5.04 | — |
| Weighted avg. shares (diluted) | 1.64M | 115,493 | 1.87M | 1.34M | — |
| Banking | |||||
| Net interest income | — | $100,000 | $100,000 | — | — |
| Deposits | — | — | $6,480 | — | — |
| Balance sheet | |||||
| Cash & equivalents | $334,005 | $1.92M | $2.58M | $8.42M | $504,749 |
| Short-term investments | — | — | $2.89M | — | — |
| Current assets | $502,911 | $2.21M | $5.59M | $8.58M | $509,615 |
| PP&E, net | $17,319 | $19,364 | $24,827 | $12,592 | $18,564 |
| Intangibles | $9.84M | — | — | — | — |
| Total assets | $10.48M | $2.51M | $5.95M | $8.65M | $651,641 |
| Current liabilities | $7.97M | $1.53M | $1.04M | $975,676 | $2.22M |
| Long-term debt | — | — | — | — | $91,021 |
| Total debt | — | — | — | — | $91,021 |
| Total liabilities | $8.22M | $1.80M | $1.90M | $975,676 | $2.28M |
| Shareholders' equity | $2.25M | $709,152 | $4.06M | $7.68M | -$1.76M |
| Net debt | — | — | — | — | -$413,728 |
| Shares outstanding | 202,362 | 163,093 | 2.01M | 1.70M | 9.31M |
| Cash flow statement | |||||
| Operating cash flow | -$9.48M | -$7.33M | -$5.58M | -$2.67M | -$300,336 |
| Capital expenditure | — | — | $19,046 | — | — |
| Free cash flow | — | — | -$5.60M | — | — |
| Investing cash flow | -$3.06M | $2.92M | -$2.83M | — | — |
| Financing cash flow | $10.95M | $3.76M | $2.57M | $10.58M | $687,932 |
| Depreciation & amortization | $290,107 | $5,463 | $6,811 | $5,972 | $6,218 |
| Stock-based compensation | $932,967 | $259,744 | $181,960 | $237,547 | $910,067 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.